153 related articles for article (PubMed ID: 12166950)
1. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
Pandey A; Volkots DL; Seroogy JM; Rose JW; Yu JC; Lambing JL; Hutchaleelaha A; Hollenbach SJ; Abe K; Giese NA; Scarborough RM
J Med Chem; 2002 Aug; 45(17):3772-93. PubMed ID: 12166950
[TBL] [Abstract][Full Text] [Related]
2. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
Kelly LM; Yu JC; Boulton CL; Apatira M; Li J; Sullivan CM; Williams I; Amaral SM; Curley DP; Duclos N; Neuberg D; Scarborough RM; Pandey A; Hollenbach S; Abe K; Lokker NA; Gilliland DG; Giese NA
Cancer Cell; 2002 Jun; 1(5):421-32. PubMed ID: 12124172
[TBL] [Abstract][Full Text] [Related]
3. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
[TBL] [Abstract][Full Text] [Related]
4. Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
Matsuno K; Ushiki J; Seishi T; Ichimura M; Giese NA; Yu JC; Takahashi S; Oda S; Nomoto Y
J Med Chem; 2003 Nov; 46(23):4910-25. PubMed ID: 14584942
[TBL] [Abstract][Full Text] [Related]
5. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.
Hennequin LF; Stokes ES; Thomas AP; Johnstone C; Plé PA; Ogilvie DJ; Dukes M; Wedge SR; Kendrew J; Curwen JO
J Med Chem; 2002 Mar; 45(6):1300-12. PubMed ID: 11881999
[TBL] [Abstract][Full Text] [Related]
6. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
[TBL] [Abstract][Full Text] [Related]
7. Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives.
Matsuno K; Ichimura M; Nakajima T; Tahara K; Fujiwara S; Kase H; Ushiki J; Giese NA; Pandey A; Scarborough RM; Lokker NA; Yu JC; Irie J; Tsukuda E; Ide S; Oda S; Nomoto Y
J Med Chem; 2002 Jul; 45(14):3057-66. PubMed ID: 12086491
[TBL] [Abstract][Full Text] [Related]
8. Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor.
Heath JA; Mehrotra MM; Chi S; Yu JC; Hutchaleelaha A; Hollenbach SJ; Giese NA; Scarborough RM; Pandey A
Bioorg Med Chem Lett; 2004 Oct; 14(19):4867-72. PubMed ID: 15341941
[TBL] [Abstract][Full Text] [Related]
9. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.
Hennequin LF; Thomas AP; Johnstone C; Stokes ES; Plé PA; Lohmann JJ; Ogilvie DJ; Dukes M; Wedge SR; Curwen JO; Kendrew J; Lambert-van der Brempt C
J Med Chem; 1999 Dec; 42(26):5369-89. PubMed ID: 10639280
[TBL] [Abstract][Full Text] [Related]
10. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
[TBL] [Abstract][Full Text] [Related]
11. Potent and selective inhibitors of PDGF receptor phosphorylation. 2. Synthesis, structure activity relationship, improvement of aqueous solubility, and biological effects of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
Matsuno K; Nakajima T; Ichimura M; Giese NA; Yu JC; Lokker NA; Ushiki J; Ide S; Oda S; Nomoto Y
J Med Chem; 2002 Sep; 45(20):4513-23. PubMed ID: 12238930
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.
Boschelli DH; Wu Z; Klutchko SR; Showalter HD; Hamby JM; Lu GH; Major TC; Dahring TK; Batley B; Panek RL; Keiser J; Hartl BG; Kraker AJ; Klohs WD; Roberts BJ; Patmore S; Elliott WL; Steinkampf R; Bradford LA; Hallak H; Doherty AM
J Med Chem; 1998 Oct; 41(22):4365-77. PubMed ID: 9784112
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor beta-receptor (beta-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases.
Zaman GJ; Vink PM; van den Doelen AA; Veeneman GH; Theunissen HJ
Biochem Pharmacol; 1999 Jan; 57(1):57-64. PubMed ID: 9920285
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
DeAngelo DJ; Stone RM; Heaney ML; Nimer SD; Paquette RL; Klisovic RB; Caligiuri MA; Cooper MR; Lecerf JM; Karol MD; Sheng S; Holford N; Curtin PT; Druker BJ; Heinrich MC
Blood; 2006 Dec; 108(12):3674-81. PubMed ID: 16902153
[TBL] [Abstract][Full Text] [Related]
15. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit.
Gazit A; Yee K; Uecker A; Böhmer FD; Sjöblom T; Ostman A; Waltenberger J; Golomb G; Banai S; Heinrich MC; Levitzki A
Bioorg Med Chem; 2003 May; 11(9):2007-18. PubMed ID: 12670652
[TBL] [Abstract][Full Text] [Related]
16. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
[TBL] [Abstract][Full Text] [Related]
17. Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. Part 4: structure-activity relationships for substituents on the quinazoline moiety of 4-[4-(N-substituted(thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
Matsuno K; Seishi T; Nakajima T; Ichimura M; Giese NA; Yu JC; Oda S; Nomoto Y
Bioorg Med Chem Lett; 2003 Sep; 13(18):3001-4. PubMed ID: 12941321
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
[TBL] [Abstract][Full Text] [Related]
19. Identification of potent and selective inhibitors of PDGF receptor autophosphorylation.
Furuta T; Sakai T; Senga T; Osawa T; Kubo K; Shimizu T; Suzuki R; Yoshino T; Endo M; Miwa A
J Med Chem; 2006 Apr; 49(7):2186-92. PubMed ID: 16570914
[TBL] [Abstract][Full Text] [Related]
20. Topological designing of 4-piperazinylquinazolines as antagonists of PDGFR tyrosine kinase family.
Khadikar PV; Shrivastava A; Agrawal VK; Srivastava S
Bioorg Med Chem Lett; 2003 Sep; 13(18):3009-14. PubMed ID: 12941323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
